Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Industry Criticized Again at Chuikyo Meeting
July 26, 2010
- Test for Predicting Efficacy of IFN Recommended for Approval as Advanced Technology
July 26, 2010
- Use of New Drugs Increasing in Cancer Therapy: CareNet
July 26, 2010
- Most Member Pharmacies Have Correctly Understood Significance of Premium: NPhA
July 26, 2010
- Nippon Chemiphar Aims at Sales of ¥30.0 Bil. with Generics in FY2012
July 26, 2010
- Interest Shown in Development of 3 More Unapproved Drugs
July 26, 2010
- Drug Market in Japan to Grow 3-6% in 2010-2014: IMS Japan
July 26, 2010
- Takeda Confident about Actos Data
July 26, 2010
- Healthcare & Welfare Cooperative Union to Jointly Buy Drugs for Member Med Facilities
July 26, 2010
- Sepracor to Be Renamed Sunovion Pharmaceuticals
July 26, 2010
- Market for Psychoneurotics to Expand to ¥453.2 Bil. in 2010: Fuji-Keizai
July 26, 2010
- OIG Asks FDA to Inspect More Overseas Trial Sites
July 26, 2010
- US Diabetes Market Remains Attractive: Datamonitor
July 26, 2010
- Terumo Aims at Sales of \1 Tril. within 10 Years: New President Shintaku
July 26, 2010
- Only 93 Apply for 750-Employee Early Retirement Program: Medipal
July 26, 2010
- Pfizer Signs Clinical Trial Partnership Agreement with NHO
July 26, 2010
- Banyu to Recruit Subjects in More Prefectures for PII Trial of MK-8669
July 19, 2010
- OHARA Pharm. Licenses Erwinase from EUSA Pharma
July 19, 2010
- NEW PRODUCTS
July 19, 2010
- Torii to Enter PIII for Sublingual Desensitization Therapy for Pollinosis
July 19, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…